GFP mutagenesis amplification: use of a fluorescence-antibiotic resistance fusion dual reporter construct to provide quantitative and highly sensitive detection of mutations
View Patent ↗A reversion mutation assay that is unique in providing a quantitative readout for mutagenesis. This assay is based on the creation of a functional GFP-β-lactamase fusion protein as a reporter providing both antibiotic resistance and fluorescence. This dual reporter is placed in a multicopy plasmid to increase the number of targets, with a reversion site at the N-terminus. Rare mutations at the reversion site allow read-through of the fusion protein, producing both beta-lactamase (providing antibiotic resistance) and GFP (emitting fluorescence). In the presence of carbenicillin, beta-lactamase production confers a selective advantage that allows amplification of mutant plasmids, raising the level of fluorescence emitted by GFP to levels that are detectable by fluorimetry. A window of time can be found where fluorescence is proportional to the number of mutation events at the reversion site, making fluorescence a quantitative measure of mutagenesis. Quantitative (as opposed to binary) detection of mutations allows substantial savings in test sample. This has applications in drug discovery, allowing high-throughput screening for DNA-targeting compounds and early pre-screening of leads for potential carcinogenic activity. The increased sensitivity of this assay also facilitates monitoring complex environmental samples.
1. A method for detecting and quantitatively measuring the mutagenic potency of a test substance, the method comprising:
a) providing a test substance,
b) providing a functional quantitative reporter-antibiotic resistance fusion construct to act as a dual reporter, wherein the dual reporter comprises an antibiotic reversion reporter and a quantitative reporter fused together in the same open reading frame and under the control of the same promoter, wherein the dual reporter possesses a reversion site at the N-terminus of the quantitative reporter-antibiotic resistance operon, wherein the dual reporter is cloned into a multicopy plasmid, and wherein mutations at the reversion site allow read-through of the fusion protein producing both an antibiotic resistance protein and a quantitative reporter protein, and further wherein, in the presence of an antibiotic, the production of the antibiotic resistance protein confers a selective advantage that causes amplification of mutant plasmids, thereby raising the level of quantitative reporter protein wherein the level of quantitative reporter protein is proportional to the number of mutation events at the reversion site,
c) transforming a host cell with the multicopy plasmid,
d) contacting the host cell to the test substance to induce mutations at the reversion site,
e) amplifying the plasmids that have mutations at the reversion site,
f) measuring the level of quantitative reporter protein, wherein the level of quantitative reporter protein is quantitatively proportional to the number of mutation events at the reversion site and therefore to the mutagenic potency of the test substance.
2. A method for detecting and quantitatively measuring the mutagenic potency of a test substance, the method comprising:
a) providing a test substance,
b) providing a functional fluorescence-beta-lactamase fusion construct to act as a dual reporter, wherein the dual reporter comprises an antibiotic reversion reporter and a quantitative fluorescence reporter fused together in the same open reading frame and under the control of the same promoter, wherein the dual reporter possesses a reversion site at the N-terminus of the fluorescence-beta-lactamase operons, wherein the dual reporter is cloned into a multicopy plasmid, and wherein mutations at the reversion site allow read-through of the fusion protein producing both beta-lactamase and fluorescence protein, and further wherein, in the presence of an antibiotic, beta-lactamase production confers a selective advantage that causes amplification of mutant plasmids, thereby raising the level of fluorescence emitted by fluorescence protein to levels that are detectable by fluorimetry, wherein fluorescence is proportional to the number of mutation events at the reversion site,
c) transforming a host cell with the multicopy plasmid,
d) contacting the host cell to the test substance to induce mutations at the reversion site,
e) amplifying the plasmids that have mutations at the reversion site,
f) measuring the fluorescent signal, wherein the amplitude of the fluorescent signal is quantitatively proportional to the number of mutation events at the reversion site and therefore to the mutagenic potency of the test substance.
3. The method of claim 1 wherein the assay is sufficiently sensitive to detect mutation frequencies of 1 in 10 8 nucleotides.
4. The method of claim 1 wherein the method does not use GFP as a transcriptional reporter.
5. The method of claim 1 wherein the amplitude of the quantitative reporter signal of the assay is proportional to mutation frequency after normalization for differences in copy number.
6. The method of claim 1 wherein reversion mutants are amplified in two steps: (i) the mutant plasmid becomes homoplasmic, and (ii) the reversion mutant cells grow preferentially under antibiotic selection.
7. The method of claim 1 wherein the selection antibiotic is bacteriostatic but not bacteriocidal.
8. The method of claim 2 wherein the quantitative fluorescence reporter is superfolder green fluorescent protein.
9. The method of claim 1 wherein functional expression of beta-lactamase gene is suppressed.
10. The method of claim 2 wherein the mutagenic effect can be determined as the area under the curve of fluorescence relative to that of an untreated control representing spontaneous mutations.
11. The method of claim 1 wherein the method is performed as part of high-throughput screening for DNA-targeting compounds.
12. The method of claim 1 wherein the method is performed using 96-well-format.
13. A functional fluorescence-beta-lactamase fusion construct to act as a dual quantitative reporter, wherein the dual reporter comprises an antibiotic reversion reporter and a quantitative reporter fused together in the same open reading frame and under the control of the same promoter, wherein the dual reporter possesses a reversion site at the N-terminus, wherein the dual reporter is adapted to be cloned into a multicopy plasmid, and wherein mutations at the reversion site allow read-through of the fusion protein producing both and antibiotic resistance protein and a quantitative reporter protein.
14. The dual reporter construct of claim 13 wherein the antibiotic resistance gene confers resistance against beta lactam antibiotics and the quantitative reporter protein is a fluorescence protein.
15. The dual reporter construct of claim 13 cloned into a multicopy plasmid.
16. The method of claim 1 for quantitatively measuring the mutagenic potency of a test substance, wherein the quantitative reporter may be detected by fluorometry or spectrophotometry or colorimetry.
17. The method of claim 16 for quantitatively measuring the mutagenic potency of a test substance, wherein the quantitative reporter is selected from a fluorescent, luminescent or colorimetric marker.
18. The quantitative reporter-antibiotic resistance fusion dual reporter construct of claim 13 , wherein the quantitative reporter may be detected by fluorometry or spectrophotometry or colorimetry.
19. The quantitative reporter-antibiotic resistance fusion dual reporter construct of claim 18 , wherein the quantitative reporter is selected from a fluorescent, luminescent or colorimetric marker.